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Abstract
Transforming growth factor-bs (TGF-b1–3) are cytokines that regulate the proliferation, differentiation, and survival of
various cell types. The present study describes the induction of TGF-b1–3 in the rat after focal ischemia at 3 h, 24 h, 72 h
and 1 month after transient (1 h) or permanent (24 h) middle cerebral artery occlusion (MCAO) using in situ hybridization
histochemistry and quantitative analysis. Double labeling with different markers was used to identify the localization of TGF-
b mRNA relative to the penumbra and glial scar, and the types of cells expressing TGF-bs. TGF-b1 expression increased 3 h
after MCAO in the penumbra and was further elevated 24 h after MCAO. TGF-b1 was present mostly in microglial cells but
also in some astrocytes. By 72 h and 1 month after the occlusion, TGF-b1 mRNA-expressing cells also appeared in microglia
within the ischemic core and in the glial scar. In contrast, TGF-b2 mRNA level was increased in neurons but not in astrocytes
or microglial cells in layers II, III, and V of the ipsilateral cerebral cortex 24 h after MCAO. TGF-b3 was not induced in cells
around the penumbra. Its expression increased in only a few cells in layer II of the cerebral cortex 24 h after MCAO. The
levels of TGF-b2 and -b3 decreased at subsequent time points. Permanent MCAO further elevated the levels of all 3
subtypes of TGF-bs suggesting that reperfusion is not a major factor in their induction. TGF-b1 did not co-localize with
either Fos or ATF-3, while the co-localization of TGF-b2 with Fos but not with ATF-3 suggests that cortical spreading
depolarization, but not damage to neural processes, might be the mechanism of induction for TGF-b2. The results imply
that endogenous TGF-bs are induced by different mechanisms following an ischemic attack in the brain suggesting that
they are involved in distinct spatially and temporally regulated inflammatory and neuroprotective processes.
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Introduction
Three separate genes encode TGF-b1, -b2, and -b3 [1,2]. TGF-
bs affect cell proliferation, differentiation, and extracellular matrix
formation in a variety of tissues [3] by means of serine-threonine
kinase domain-containing TGF-b receptors [4,5]. In the normal
brain, TGF-b1 immunoreactivity is present in the epithelial and
meningeal cells of the choroid plexus [6]. In situ hybridization
histochemistry also indicated the expression of TGF-b1 in some
restricted brain regions [7]. TGF-b2 and -b3 were constitutively
present in several brain regions as, confirmed at the mRNA [7]
and protein levels [6], and their expression patterns greatly
overlapped, although the expression level of TGF-b2 was
considerably higher than that of TGF-b3 [8]. In the cerebral
cortex, TGF-b2 expression was very intense in layer V Layers III
and IV also contained TGF-b2 and –b3, respectively, while TGF-
bs were absent in the caudate putamen [6,7].
Among the potential neural functions of the TGF-bs, their
involvement in neuroprotection is the most established [8–15].
The administration of TGF-b1 into the brain reduced infarct size
in experimental models of ischemia [16–18], while antagonizing
the endogenous actions of TGF-b1 with an injection of a soluble
TGF-b type II receptor, which binds TGF-b1 and prevents its
biological actions, resulted in a dramatic increase in infarct area
[19]. Although the involvement of other subtypes of TGF-bs in
ischemia has not been established, their neuroprotective actions
are conceivable based on their involvement in the survival of
midbrain dopaminergic neurons [20–22] and motoneurons [23]
and in the modulation of plasticity in hippocampal neurons [24].
In addition to neuroprotection, TGF-bs may also participate in
regenerative processes, as they are known to increase neurogenesis
in the adult dentate gyrus [25], and subventricular zone [26] and
promote a neuronal cell fate for cortical and hippocampal
progenitors [27].
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The induction of TGF-b1 has been investigated following
middle cerebral artery occlusion (MCAO), a model of focal
ischemia [28]. An increase in TGF-b1 mRNA in the cingulate
cortex as an early event was followed by the induction of TGF-b1
within the infarct area [29,30]. Delayed expression of TGF-b1 has
also been shown by Northern hybridization [31]. Activated
microglia and invading macrophages appearing within the infarct
area [32] were suggested to be the major sources of TGF-b1 after
MCAO [33]. The induction of other subtypes of TGF-bs is also
conceivable given that different TGF-bs were induced in
necrotizing brain lesions [34] and that the expression of TGF-
b2, but not TGF-b1, was correlated with the deposition of scar
tissue in lesioned spinal cord [35]. In fact, our previous qualitative
report on the induction of TGF-bs 24 h following transient
MCAO suggested their involvement in brain ischemia [7]. In the
present study, we addressed the following questions to describe the
time course, distribution, and cell types involved in the induction
of TGF-bs following MCAO and to understand the mechanisms
of their induction: 1. How are TGF-b1, -b2 and -b3 mRNAs
distributed following 1 h transient and permanent (24 h) MCAO
in the rat brain? The penumbra was visualized using immunola-
beling of heat shock protein 70 (Hsp70) as previously described
[36,37]. 2. What is the time course of induction of TGF-b1, -b2
and -b3 mRNA following MCAO? In situ hybridization histo-
chemistry, which we previously used to describe the distribution of
all 3 TGF-bs in the normal brain [7], was used at 3 h, 24 h, 72 h,
and 1 month after MCAO to address this question and was
followed by a quantitative analysis of the number of TGF-b-
expressing cells and the mRNA levels in individual cells. 3. Which
cell types express the different subtypes of TGF-bs following
MCAO and what is the mechanism of their induction? In situ
hybridization histochemistry in combination with immunolabeling
for neuronal (NeuN), astrocyte (glial fibrillary acidic protein –
GFAP), and microglial (ionized calcium-binding adapter molecule
1 - Iba1) markers was applied to identify cells that expressed the 3
different subtypes of TGF-bs in the ischemic rat brain. 4. What
mechanisms activate TGF-bs following ischemia? TGF-bs were
double stained with the immediate early genes Fos and activating
transcription factor-3 (ATF-3), markers of neuronal activation and
axonal damage, respectively [38], to establish the involvement of
these processes in the induction of TGF-bs.
Materials and Methods
Ethics Statement
The Animal Examination Ethical Council of the Animal
Protection Advisory Board at Semmelweis University, Budapest
specifically approved this study. Thus, the procedures involving
rats were carried out according to experimental protocols that
meet the guidelines of the Animal Hygiene and Food Control
Department, Ministry of Agriculture, Hungary, which is in
accordance with EU Directive 2010/63/EU for animal experi-
ments. A total of 48 adult, male Wistar rats (300–450 g body
weight; Charles Rivers Laboratories, Hungary) were used in this
study. All efforts were made to minimize the number of animals
used, and their suffering. The animals were kept in standard
laboratory conditions with 12-h light, 12-h dark periods (lights on
at 6.00 a.m.), and were supplied with dry rat food and drinking
water ad libitum. The rats were maintained 3 per cage at a
temperature of 2261uC and anaesthetized with an intramuscular
injection (0,2 ml/300 g body weight) of ketamine (60 mg/ml) and
xylazine (8 mg/ml) for middle cerebral artery occlusion, transcar-
dial perfusion, and decapitation.
Middle Cerebral Artery Occlusion
Focal ischemia was induced using a modified intraluminal
suture method described previously [39]. Briefly, the left common,
internal and external carotid arteries were exposed through a
midline incision in the neck and then carefully dissected from the
surrounding tissues under an operating microscope. After electro-
coagulation of the external and common carotid arteries, a 3-0
silicon rubber-coated monofilament (Doccol, Redlands, CA) was
inserted through the common carotid artery into the internal
carotid artery to 18 to 20 mm beyond the carotid bifurcation at
the base of the middle cerebral artery. The pterygopalatine branch
of the internal carotid artery was exposed before the insertion to
prevent the filament from entering into the pterygopalatine. An
atraumatic aneurysm clip (Codman, Johnson and Johnson, Le
Locle, NE, Switzerland) was placed on the internal carotid artery
to prevent bleeding. The clip and the monofilament were removed
1 h later for transient ischemia and left in place for 24 h for
permanent ischemia. The incision was then sutured. After the
required survival period, the brains of the rats intended for single
in situ hybridization histochemistry were dissected and cut
coronally at 1 mm rostral to bregma. The anterior parts of the
brains were stained with 2,3,5-triphenyltetrazolium chloride
(TTC) and the posterior parts were frozen for in situ hybridization
histochemistry. The rats intended for double labeling with in situ
hybridization histochemistry and immunohistochemistry were
transcardially perfused before their brains were removed.
Allocation of Operated Animals into Experimental
Groups
Five rats were used in each of the following 5 groups: (1) 3 h
following 1 h MCAO, (2) 24 h following 1 h MCAO, (3) rats with
a permanently occluded middle cerebral artery 24 h following
MCAO, (4) 72 h following 1 h MCAO, and (5) 1 mo following 1 h
MCAO. The number of perfused animals included an additional 4
rats for some of the groups (rats at 24 h, 72 h and 1 mo following
1 h MCAO). A further 11 sham-operated rats were used at
different time points (11 rats total, 2 for each time point and 3
additional rats for perfusion at 24 h, 72 h and 1 month following
MCAO).
In situ Hybridization Histochemistry
Brains of 33 rats (5 in all 5 groups and 2 sham-operated for each
4 time points) were removed and the fresh tissue was quickly
frozen on dry ice, and kept at 280uC. Serial coronal sections
(12 mm thick) were cut using a cryostat from bregma level 1 mm to
-6 mm [40], mounted on positively charged slides (Superfrost-
PlusH, Fisher Scientific, Pittsburgh, PA), dried, and stored at
280uC until use. For in situ hybridization, DNA probes developed
for the description of TGF-bs in the normal brain were used,
which represent 231–647 bp of GenBank accession number
NM_021578.2) for TGF-b1, 870–1155 bp of GenBank accession
number NM_031131.1 for TGF-b2, and 1046–1343 bp of
GenBank accession number NM_013174.1 for TGF-b3 [7]. The
primers were chosen to generate probes that recognize all known
RNA species for the particular gene. The specificities of the probes
were shown by resulting in identical expression pattern as non-
overlapping additional probes for TGF-bs [7]. [35S]UTP-labeled
riboprobes were generated from the DNA probes containing T7
and T3 RNA polymerase recognition sites using a MAXIscript
transcription kit (Ambion, Austin, TX). Antisense riboprobes were
prepared using T7 RNA polymerase while sense control probes
were prepared using T3 RNA polymerase. The preparation of
tissue was performed using mRNAlocator Kit (Ambion), according
TGF-beta Expression following MCAO
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Figure 1. The induction of TGF-b1, -b2, and –b3 mRNA at 3 h and 24 h after middle cerebral artery occlusion (MCAO). Dark-field
photomicrographs of in situ hybridization sections show the expression of TGF-bmRNAs. The lesion sites are indicated by the star symbols (*) and the
borders of the lesions are demarcated by black and white dots. A: Giemsa counterstaining demonstrates the position of the lesion in the caudate
putamen 3 h after MCAO. B: The same field of the same section is shown in a dark field image. TGF-b1 mRNA is induced around the lesion. C: TGF-b2
mRNA is present ipsilateral to the lesion. The normal distribution of TGF-b2 can be observed in layers II and V of the cerebral cortex without any
apparent increase in the expression level. D: TGF-b1 expression is induced around the lesion in the cerebral cortex 24 h following MCAO. E: TGF-b1
expression is also induced in the peri-infarct area of the caudate putamen. F: TGF-b2 is induced in layers II, III, and V of the ipsilateral cerebral cortex.
G: TGF-b3 has a somewhat elevated expression level in some cells of layer II of the cerebral cortex. TGF-b3 is normally present in layer IV of the
cerebral cortex and is not induced in this location. Abbreviations: ac – anterior commissure, cc – corpus callosum, CP - caudate putamen, LV - lateral
ventricle. Scale bars = 1 mm.
doi:10.1371/journal.pone.0046731.g001
TGF-beta Expression following MCAO
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to the manufacturer’s instructions. For hybridization, we used
80 ml hybridization buffer (mRNAlocator Kit; Ambion) and
labeled probes of 1 million DPM activity per slide. Washing
procedures included a 30 min incubation in RNase A followed by
decreasing concentrations of sodium-citrate buffer (pH=7.4) at
room temperature and then at 65uC. Following subsequent
dehydration and drying, the slides were dipped in NTB nuclear
track emulsion (Eastman Kodak) and stored at 4uC for 3 weeks.
Then, the slides were developed and fixed with Kodak Dektol
developer and Kodak fixer, respectively, counterstained with
Giemsa, and coverslipped with Cytoseal 60 (Stephens Scientific,
Riverdale, NJ, USA).
Quantitation of in situ Hybridization Data
A cell was considered to express TGF-b if the number of
autoradiography grains accumulated in a seemingly Gaussian
distribution around a center was at least 3 times higher than the
background level in an area corresponding to an average cell size
(a circle with a diameter of 25 mm). The background typically
contained of 3–4 grains, but always less than 7 grains, per cell in
the in situ hybridization histochemistry. The number of labeled
cells was counted in rectangles (400 mm wide by 200 mm high)
along the outside borders of the lesions. Cell counts were confined
to specific cortical layers, as well as 1 mm lateral and 1 mm medial
to the border of the lesion in layer II of the cerebral cortex (within
the lesion and in the ipsilateral healthy tissue, respectively), in the
caudate putamen, in the corresponding locations in the contra-
lateral side and in sham-operated animals. In addition, the
number of autoradiography grains was counted in 3 randomly
selected TGF-b mRNA-expressing cells in each of the 5 rectangles
analyzed at different time points after MCAO. Statistical analyses
were performed using Prism 5 for Windows (GraphPad Software
Inc.). In the first type of analysis, both the number of cells and the
number of autoradiography grains measured in different brain
regions 24 h following MCAO were compared with the corre-
sponding data obtained from the contralateral hemisphere using
Students t-tests. In the second type of analysis, the number of
TGF-b mRNA-expressing cells and the number of autoradiogra-
phy grains measured in these cells in the 6 groups (sham-operated
rats 24 h following MCAO, rats at 3 h and 24 h following 1 h
MCAO, rats with a permanently occluded middle cerebral artery
at 24 h following MCAO, rats at 72 h and 1 mo following 1 h
MCAO) were compared using one-way ANOVA followed by
Bonferronis multiple comparison post-hoc tests.
Cresyl-violet Staining
Parallel series of sections from the MCAO rats were Nissl
stained for identification of the border of the lesion. The sections
were stained with 0.1% cresyl-violet dissolved in PB, and then
differentiated in 96% ethanol containing acetic acid. The sections
were dehydrated and coverslipped with Cytoseal 60 (Stephens
Scientific).
Tissue Collection for Immunolabeling
The rats (n = 15; 4 animals following MCAO and a sham-
operated control at 3 time points: 24 h, 72 h, and 1 month
following the operation) were deeply anesthetized and transcar-
dially perfused with 150 ml of saline followed by 300 ml of 4%
Figure 2. The expression of TGF-b proteins in different brain regions around an ischemic lesion at 24 h following a 1 h transient
MCAO. The number of cells was counted in 2006400 mm areas (0.08 mm2) of coronal brain sections in cortical layers I-VI and in the caudate
putamen (CP). The number of autoradiography grains was counted above TGF-b-positive cell nuclei indicated by the accumulation of
autoradiography grains. Measurements were performed around the ischemic lesion (dark gray) and in the corresponding brain area on the
contralateral side of the brain (light gray). Sections from 5 animals were involved in the analysis. A–C: The number of cells expressing TGF-b1, -b2, and
-b3 in 0.08 mm2. D-F: The number of autoradiography grains proportional to the mRNA level of TGF- b1, -b2, and -b3 in single cells. The values around
the ischemic lesion and in the corresponding brain area on the contralateral side of the brain were compared using paired Students t-tests, where
data obtained from the same section formed the pairs to eliminate variation from the labeling intensity of an individual staining. The star symbol (*)
indicates brain regions, in which the number of TGF-b-expressing cells or the mRNA level of the particular subtype of TGF-b in single cells was
significantly (p,0.05) elevated.
doi:10.1371/journal.pone.0046731.g002
TGF-beta Expression following MCAO
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paraformaldehyde prepared in phosphate buffer (PB; pH=7.4).
The brains were removed and postfixed in 4% paraformaldehyde
for 24 h and then transferred to PB containing 20% sucrose for 2
days. Serial coronal brain sections were cut at 20 mm on a cryostat
between 4.0 and 26.0 mm bregma levels. The brain sections were
collected in such a way that consecutive sections were mounted on
12 parallel slides. These parallel slides were used for different
combinations of in situ hybridization and immunohistochemistry to
perform the large number of double labeling experiments
described below.
Immunohistochemistry
Slide-attached sections were pretreated with 3% hydrogen
peroxide for 15 min followed by 1% bovine serum albumin in PB
containing 0.5% Triton X-100 for 30 min at room temperature.
Then, parallel series of sections (every 13th section per brain) were
placed in one of the following primary antisera for 24 h at room
temperature: rabbit anti-Hsp70 (1:1000; Abcam, Cambridge, UK,
cat. number: ab79852) as a marker of cells in the penumbra,
mouse anti-NeuN as a marker of neuronal nuclei (1:500; Millipore,
Billerica, MA, cat. number: MAB377), mouse anti-glial fibrillary
acidic protein (GFAP) as a marker of astrocytes (1:300; Santa Cruz
Biotechnology, Delaware, CA, USA; cat. number: sc-33673),
rabbit anti-ionized calcium-binding adapter molecule 1 (Iba1) as a
marker of microglial cells (1:1000; Wako, cat. number: 019–
197419), rabbit anti-Fos to label activated neurons (1:25000; Santa
Cruz Biotechnology, cat. number: c-fos (4) sc-52), and rabbit anti-
activating transcription factor-3 (ATF-3) as a marker of neurons
with damaged neuronal processes (1:300; Santa Cruz Biotechnol-
ogy, cat. number: ATF-3 (C-19): sc-188). Subsequently, the
Figure 3. The induction of TGF-b1, - b2, and -b3 mRNA 72 h and 1 mo after MCAO. In situ hybridization sections show the expression of
TGF-b mRNA. The infarct areas are indicated by the star symbol (*) and the borders of the infarcts are demarcated with white dots. A: TGF-b1
expression is induced at the perimeter of the lesion as well as within the infarct area 72 h after MCAO. High magnification bright field
photomicrographs demonstrate that TGF-b1 mRNA accumulates above cell bodies within the infarct area (Aa), as well as in the corpus callosum (Ab).
The locations of these pictures are indicated by the arrowheads in the left panel. B: TGF-b2 is present in layers II, III, and V of the cerebral cortex. Only
a few cells demonstrate increased expression level of TGF-b2 in the vicinity of the border of the lesion at 72 h after MCAO. C: TGF-b3 is present in
some neurons in layer IV of the cerebral cortex, but the level of expression is not higher than that in normal animals D: The induction of TGF-b1 mRNA
is demonstrated 1 month after MCAO. TGF-b1 mRNA is abundant within the infarct area except for in a relatively small core region. The field indicated
by the large black arrowhead in A is enlarged and shown in bright-field in the inlet to demonstrate that even the densest TGF-b1 signal represents
labeling of individual cells as autoradiography grains accumulated above cell bodies. E: TGF-b2 mRNA is present in a few cells at the perimeter of the
infarct area. Outside the lesion, TGF-b2 mRNA is distributed in the cerebral cortex as in intact animals but is not induced above normal levels.
Abbreviations: ac – anterior commissure, cc – corpus callosum, CP - caudate putamen, LV - lateral ventricle. Scale bar = 2 mm for A and E, 1 mm for C,
and 50 mm for B.
doi:10.1371/journal.pone.0046731.g003
Figure 4. The time course of TGF-b protein expression following MCAO. The numbers of cells within 200 x 400 mm areas (0.08 mm2) of
coronal brain sections in cortical layer II were counted immediately outside the lesion (dark gray) and 1 mm medial to the border of the lesion within
the infarct area (light gray). The number of autoradiography grains was counted above the TGF-b-positive cell nuclei, indicated by autoradiography
grain accumulation. Sections from at least 3 brains of the following groups of animals were included in the analysis: sham-operated rats 24 h
following MCAO, rats at 3 h and 24 h following 1 h MCAO, rats with a permanently occluded middle cerebral artery 24 h following MCAO, and rats at
72 h and 1 mo following 1 h MCAO. A–C: The number of cells expressing TGF-b1, -b2, and -b3 in 0.08 mm2. D-F: The number of autoradiography
grains proportional to the mRNA levels of TGF-b1, -b2, and -b3 in single cells. Values at different time points were compared using one-way ANOVA
followed by Bonferronis multiple comparisons tests for consecutive time points. The star symbol (*) indicates time points between which the number
of TGF-b-expressing cells or the mRNA level of the particular subtype of TGF-b in single cells significantly (p,0.05) changed.
doi:10.1371/journal.pone.0046731.g004
TGF-beta Expression following MCAO
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sections were incubated in either biotinylated anti-rabbit second-
ary antibody (1:1000; Vector Laboratories, Burlingame, CA, USA)
or anti-mouse secondary antibody (1:1000; Jackson ImmunoR-
esearch, West Grove, PA), for 1 h followed by incubation in
avidin-biotin-horseradish peroxidase complex (1:500; Vector
Laboratories) for 1 h. Finally, the sections were treated with
0.06% DAB and 0.003% H2O2 in Tris hydrochloride buffer
(0.05 M, pH=8.2) for 10 min, and coverslipped with Cytoseal 60
(Stephens Scientific).
Figure 5. The induction of TGF-b mRNA by 24 h permanent occlusion of the middle cerebral artery. The infarct area is indicated by star
symbol (*) and its border is demarcated with black or white dots. A: TTC staining demonstrates the effect of ischemia on brain tissue. B: TGF-b1
expression is induced in the peri-infarct area of the lesion. C: TGF-b2 is induced in layers II, III, and V of the ipsilateral cerebral cortex. The induction is
particularly salient in layers II and III where the labeling is much more intense ipsilateral to the lesion compared with the contralateral side. D: TGF-b3
is induced in layer II of the ipsilateral cerebral cortex. Abbreviations: cc – corpus callosum, CP - caudate putamen, LV - lateral ventricle. Scale
bars = 1 mm for B and D.
doi:10.1371/journal.pone.0046731.g005
TGF-beta Expression following MCAO
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The specificity of the antibodies used in the present study has
been validated previously. In addition, our own results also argue
for specific labeling. The anti-Hsp70 antiserum (Abcam, Cam-
bridge, UK, cat. number: ab79852) resulted in an intense western
blot band at 70kDa according to the manufacturer. In addition,
we did not observe any Hsp70 labeling in the intact brain. In turn,
Hsp70 immunoreactivity appeared in the peri-lesion area follow-
ing MCAO as expected as it is a marker of the penumbra [36,37].
The anti-NeuN antibody (Millipore, Billerica, MA, cat. number:
MAB377) labeled neurons and was confirmed by their morphol-
ogy. This antibody has been used in several previous publications
that required the validation of its specificity [41]. The anti-GFAP
antibody (Santa Cruz Biotechnology, Delaware, CA, USA; cat.
number: sc-33673) labeled a single band with the appropriate
molecular weight of approximately 50 kDA in western blot
experiments according to the manufacturer. In our study, the anti-
GFAP antibody labeled cells with morphology characteristic of
astrocytes. In addition, GFAP immunoreactivity markedly in-
creased in cells surrounding the lesion at the time points when
astroglial scar formation was expected. The anti-Iba1 antiserum
(Wako, cat. number: 019–197419) labeled cells with morphology
characteristic of resting microglia with ramified thin processes, as
well as large, ameboid-shaped activated microglia in and around
the lesions. In addition, this antiserum has been extensively used as
a marker of microglial cells in previous studies that required the
validation of its specificity [42]. The anti-Fos antiserum (Santa
Cruz Biotechnology, cat. number: c-fos (4) sc-52), a marker for
labeling activated neurons, did not label cells in the sham-operated
Figure 6. The localization of TGF-b1 and -b2 mRNA in relation to markers of the penumbra and glial scar. A: Double labeling of TGF-b1
mRNA (black in situ hybridization signal) and immunoreactivity of heat shock protein 70 (Hsp70), a marker of the penumbra (brown precipitate) 24 h
following MCAO. The lesion is indicated by star symbols (*), and the lesion border is demarcated by black dots. Black squares demarcate the outer
border of the penumbra. The framed area in Aa is shown in Ab to better appreciate the similar distribution of TGF-b1 mRNA and Hsp70 in the
penumbra. Ac is a high magnification image of the framed area in Ab and demonstrates that TGF-b1 mRNA and Hsp70 immunoreactivity are not co-
localized in the same cells. B: Double labeling of TGF-b2 mRNA (black in situ hybridization signal) and Hsp70 immunoreactivity (brown precipitate)
24 h following MCAO. Black squares demarcate the outer border of the penumbra. Within the penumbra, the majority of the TGF-b2 mRNA-
expressing cells contain Hsp70 immunoreactivity. However, TGF-b2 mRNA expressing cells but not Hsp70-immunoreactive cells are present in the
intact brain tissue. C: A glial scar can be identified based on the high density of intensely labeled GFAP-positive astrocytes. TGF-b1-expressing cells
are present within the glial scar and also within the lesion but not in the intact tissue outside the glial scar. Abbreviations: LV - lateral ventricle. Scale
bars = 1 mm for Aa, 400 mm for Ab, 100 mm for Ac, and 200 mm for both B and C.
doi:10.1371/journal.pone.0046731.g006
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rats, except for in a few restricted brain regions, in our study.
However, as expected, labeled neurons appeared in the cerebral
cortex following ischemic attack. In addition, this antiserum has
been used before as a marker of activated cells in previous studies
that required the validation of its specificity [43]. The anti-ATF-3
antiserum (Santa Cruz Biotechnology, cat. number: ATF-3 (C-19):
sc-188) did not label cells in the sham-operated rats, except for in a
few brain regions, in our study. However, as expected, labeled
neurons appeared around the lesion, as ATF-3 is a marker used for
labeling neurons with damaged neuronal processes. This antise-
rum has been used before as a marker of damaged cells in previous
studies that required the validation of its specificity [44].
Combination of Immunohistochemistry and in situ
Hybridization Histochemistry
Slide attached sections of perfused brains were first processed
for in situ hybridization, as described above. Thus, tightly bound
RNA-RNA pairs were already formed by the time immunohisto-
chemistry was performed, immediately before dipping the slides
into autoradiographic emulsion. In addition, the solutions used for
perfusion and immunohistochemistry were prepared with DAPC-
treated RNAse-free water, which ensured that the labeling
intensity of the in situ hybridization histochemistry did not
decrease significantly. The immunolabeling protocol was the same
as that used for single labeling immunohistochemistry. Immuno-
reactivity was visualized using DAB reactions, after which the in
situ hybridization procedure was continued by dipping the slides
into emulsion. Each double labeling experiment included controls,
which went through the double labeling procedure without
application of radioactive in situ hybridization probes. These
controls demonstrated that the DAB signal did not induce an
autoradiography signal.
Analysis of Double Labeling Experiments
A cell was considered TGF-b-expressing if it met the criteria
described above for single label in situ hybridization histochemistry.
A TGF-b-expressing cell was considered immunopositive if at least
half of the area of the circle containing the accumulation of
autoradiography grains contained immunoreactivity for a partic-
ular marker. For comparison, the number of TGF-b-expressing
cells and the number of double-labeled cells (TGF-b + NeuN,
GFAP, Iba1, Hsp70, Fos, or ATF-3) were counted in 4006200 mm
rectangular areas at the outside borders of the lesions in layers II
and V of the cerebral cortex and in the caudate putamen. The
percentage ratios of double-labeled TGF-b-expressing cells were
compared between different brain regions using one-way AN-
OVA.
Histological Analysis and Image Processing
The sections were examined using an Olympus BX60 light
microscope in both dark-field and bright-field. Images were
captured at 204862048 pixel resolution with a SPOT Xplorer
digital CCD camera (Diagnostic Instruments, Sterling Heights,
MI) using a 46objective for dark-field images, and 4–406objec-
tives for bright-field images. The contrast and sharpness of the
images were adjusted using the ‘‘levels’’ and ‘‘sharpness’’
commands in Adobe Photoshop CS 8.0. Full resolution was
maintained until the photomicrographs were printed, at which
point the images were adjusted to a resolution of 300 dpi.
Results
All 3 types of TGF-bs were induced in the rat brain following
MCAO. We describe the specific topographical mRNA expression
of each type of TGF-b in response to focal ischemia at different
time points following MCAO and the different cell types that
express TGF-bs. We demonstrate that TGF-b2 appears in
neurons that also show Fos activation following MCAO in the
ipsilateral cerebral cortex but not in neurons expressing ATF-3.
The Expression Patterns of TGF-b mRNAs in the Brain
Following MCAO
3 h after transient MCAO: A 1 h occlusion of the middle
cerebral artery resulted in a lesion that was histologically visible
3 h after the onset of the occlusion. The lesioned tissue lost its
structure in the lateral part of the caudate putamen as observed
using Giemsa counterstaining (Fig. 1A). TGF-bs were not present
within the infarct area but TGF-b1 was induced in the area
around the lesion. The induction of TGF-b1 was striking in the
non-lesioned area of the caudate putamen (Fig. 1B), as TGF-b1 is
not expressed in this area in sham-operated animals (not shown).
Table 1. Immunolabeling of TGF-b-expressing cells.
TGF-b1 TGF-b2 TGF-b3
layer II layer V CP layer II layer V layer II
Number of TGF-b cells/0.08 mm2 18.364.9 16.763.5 20.564.5 18.364.2 17.063.9 14.064.5
Immunolabeled cells in the % of
TGF-b cells
NeuN 3.762.8 4.763.3 5.763.9 87,163,8 84,862,7 81,163.5
GFAP 26.362.8 21.666.2 22.264.4 4.262.3 4.062.1 9.365.8
Iba1 93.763.4 94.064.6 96.064.1 3.162.6 3.562.4 6.763.4
Hsp70 7.262.2 4.863.9 5.562.9 76.367.4 69.268.9 –
Fos 4.162.2 4.763.3 5.262.7 90.263.8 91.964.6 –
ATF-3 8.461.9 7.162.6 8.564.1 2.861.9 4.362.9 –
Data on TGF-b1 is presented in 3 different locations, layer II and V of the cerebral cortex and the caudate putamen (CP). Because TGF-b2 is not expressed in the caudate
putamen, TGF-b2-expressing cells were only counted in the cerebral cortex. Similarly, data on TGF-b3 are provided only for layer II of the cerebral cortex. In the upper
row, the total number of TGF-b-expressing cells counted in a 4006200 mm rectangular-shaped area immediately outside the lesion is shown. The number of double-
labeled cells was also counted in the same field, and the calculated ratios were averaged. One-way ANOVA did not indicate significant differences between brain
regions for any of the markers.
doi:10.1371/journal.pone.0046731.t001
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TGF-b1 also appeared in the cerebral cortex. The most intense
labeling was present lateral to the lesion in the insular and frontal
somatosensory cortices. In contrast, the distribution of TGF-b2
and -b3 mRNA did not change compared with intact and sham-
operated animals at this early time point. Furthermore, induction
of these 2 subtypes was not observed (Fig. 1C).
24 h after transient MCAO: A lesion that includes a large
part of the caudate putamen as well as a large part of the ipsilateral
cerebral cortex was found 24 h after MCAO. TGF-b1 mRNA was
detected in the peri-infarct area around the lesion in all cerebral
layers (Fig. 1D) as well as in the caudate putamen (Fig. 1E). A
significant increase in the level of TGF-b1 mRNA, compared with
the corresponding contralateral brain regions of layers II-VI of the
cerebral cortex and the caudate putamen, was observed
(Figs 2A,D). TGF-b2 was also induced around the infarct area
in response to MCAO in the cerebral cortex but not in the caudate
putamen (Fig. 1F). A quantitative analysis of gene expression
revealed that in layer II, both the number of TGF-b2-expressing
cells and the level of TGF-b2 mRNA increased. The number of
TGF-b2-expressing cells, but not the TGF-b2 mRNA levels in
individual cells, increased in layer III In contrast, in layers V and
VI, which have significant basal TGF-b2 expression, the mRNA
levels increased in cells that already expressed TGF-b2, without
the recruitment of additional cells (Figs. 2 B, E). IIVII Induction of
TGF-b3 was visible only in a few cells in layer II of the cerebral
cortex in the vicinity of the lesion (Figs. 1G, 2C,F). The expression
levels of any of the TGF-bs were not higher contralateral to the
lesion than in sham-operated or intact animals.
Figure 7. TGF-b1 is induced in glial cells but not in neurons 72 h after lesion. A: Double labeling of TGF-b1 mRNA and Iba1
immunoreactivity. The border of the lesion is demarcated by black dots. The position of the high magnification image in B is shown by the large black
arrowhead. B: A high magnification image shows that the black in situ hybridization signal of TGF-b1 is located above Iba1-immunoreactive cell
bodies visualized by brown precipitate. C: Single labeled TGF-b1 mRNA expressing cells are indicated by white arrowheads, and GFAP-
immunoreactive astrocytes by black arrowheads, while double labeled cells are indicated by black arrows. D: TGF-b1 mRNA expressing neurons are
indicated by white arrowheads, and NeuN-immunoreactive neurons by black arrowheads. No double labeled neurons are present. Abbreviations: cc –
corpus callosum, LV – lateral ventricle. Scale bars = 1 mm for A, 30 mm for B, and 100 mm for C and D.
doi:10.1371/journal.pone.0046731.g007
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72 h after transient MCAO: At 72 h after MCAO, TGF-b1
expression remained elevated around the lesion (Fig. 3A) with a
further significant increase in the number of TGF-b1-expressing
neurons when compared with 24 h after MCAO (Fig. 4A). In
addition, a number of TGF-b1 mRNA expressing cells appeared
within the infarct area and in the corpus callosum (Fig. 3A). In
parallel, the levels of TGF-b2 and -b3 mRNA showed a tendency
to return to the intact levels of expression in the cerebral cortex
(Fig. 3B,C). In contrast to TGF-b1, TGF-b2 and -b3 mRNA did
not appear within the ischemic lesion (Figs. 3B,C, 4).
1 month after transient MCAO: The area of the infarct had
shrunk 1 month after MCAO. TGF-b1 expression remained very
high within the infarct area but the number of TGF-b1-expressing
cells was reduced outside of the infarct (Figs. 3D, 4A). TGF-b2 and
-b3 were no longer induced in the cerebral cortex but their pre-
lesion level of expression was retained (Fig. 3E). Some TGF-b2-
expressing cells appeared within the lesioned area (Fig. 4B,E) and
at the perimeter of the lesion.
Permanent MCAO (24 h): Permanent occlusion of the
middle cerebral artery resulted in large lesions that included the
majority of the ipsilateral caudate putamen and cerebral cortex
(Fig. 5A). Concurrently, the induction of TGF-bs became more
pronounced than following transient MCAO. TGF-b1 mRNA
occupied a larger area around the lesion than was observed 24 h
after 1 h MCAO (Fig. 5B). TGF-b2 induction remained restricted
to layers II, III, and V of the cerebral cortex. TGF-b2 expression
was induced in these layers in the vicinity of the lesioned area and
was enhanced up to the midline in the ipsilateral cerebral cortex
(Fig. 5C). Nevertheless, an induction of TGF-b2 mRNA was not
found in the contralateral hemisphere. A similar induction pattern
of TGF-b3 was observed in layer II of the ipsilateral cerebral
cortex. In contrast, the cells that express TGF-b3 in layers IV and
VI in the intact rats did not display any increase in TGF-b3
mRNA levels (Fig. 5D).
Figure 8. TGF-b2 is induced in neurons but not in glial cells 24 h after MCAO. A: Double labeling of TGF-b2 mRNA (black in situ
hybridization signal) and immunoreactivity of the microglia marker Iba1 (brown precipitate). The lesion is indicated by star symbols (*) and the lesion
border is demarcated by black dots. The positions of the high-magnification images in layer III and V of the cerebral cortex are indicated by black
arrowheads as Aa, and Ab, respectively. Iba1-immunoreactive microglia do not contain TGF-b2 mRNA in either layer of the cerebral cortex. B: Double
labeling of TGF-b2 mRNA (black in situ hybridization signal) and NeuN-immunoreactive neurons (brown precipitate). Almost all TGF-b2 mRNA-
expressing cells contained NeuN immunoreactivity in layer III (Ba), and in layer V (Bb). Examples of double-labeled cells are indicated by black arrows.
C: TGF-b2 is not expressed in astrocytes. TGF-b2 mRNA expressing neurons are indicated by white arrowheads and GFAP-immunoreactive neurons
are indicated by black arrowheads. There are no double-labeled cells present. Abbreviations: cc – corpus callosum. Scale bars = 1 mm for A, 50 mm for
Ab, 200 mm for Ba, 100 mm for Bb, and 100 mm for C.
doi:10.1371/journal.pone.0046731.g008
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Figure 9. Fos and ATF-3 content of TGF-b expressing cells 24 h after MCAO. A: Fos immunoreactive cell nuclei are present in the cerebral
cortex ipsilateral but not contralateral to the lesion. The density of Fos-ir cells is particularly high in layers II, III, and V The lesion is indicated by *. B:
Intensely labeled ATF-3-ir cells are abundant around the lesion. C: TGF-b1 mRNA (black grains) does not co-localize with Fos immunoreactivity
(brownish-reddish cell nuclei) in the cerebral cortex indicated by white arrowheads. D: TGF-b1 mRNA does not co-localize with ATF-3
immunoreactivity (brownish-reddish cell nuclei indicated by white arrowheads). E: TGF-b2 mRNA co-localizes with Fos immunoreactivity as black
autoradiography grains are located above the brownish-reddish Fos-ir cell nuclei. Double labeled neurons are indicated by black arrows. Some Fos-ir
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Distribution of TGF-bs in Relation to the Penumbra and
Astroglial Scar
Heat shock protein 70 immunoreactivity, indicative of the
penumbra, was distributed in cell bodies around the lesion 24 h
following transient MCAO but was absent within the lesion and
the intact brain tissue (Fig 6A). TGF-b1-expressing cells had a
similar distribution at this time point (Fig. 6A). However, TGF-b1
mRNA and Hsp70 immunoreactivity were typically not present in
the same cells (Table 1).
The distribution of TGF-b2 and Hsp70 overlapped within the
penumbra 24 h following MCAO. However, additional TGF-b2-
expressing cells were present in the intact brain tissue in layers II,
III, and V of the cerebral cortex (Fig. 6B). Interestingly,
approximately 75% of the cells expressing TGF-b2 within the
penumbra also contained Hsp70 (Table 1).
A glial scar was present around the lesion 1 month following
MCAO. The scar tissue was visualized by intense GFAP-
immunolabeling (Fig. 6C). TGF-b1-expressing cells were abun-
dant within the glial scar and the infarct area but were virtually
absent in the intact tissue (Fig. 6C). The majority of the TGF-b1-
expressing cells within the glial scar did not contain GFAP
(Fig. 6C). TGF-b2 and –b3 were not present in astrocytes forming
the scar tissue 1 month following MCAO (not shown).
The Cell Types Expressing TGF-bs in Response to
Transient MCAO
In the brain sections of intact and sham-operated rats, Iba1
immunohistochemistry labeled resting microglia with ramified thin
processes. At the perimeter of the lesion, intensely labeled Iba1-
positive, large, ameboid-shaped cells were present 24 h after
MCAO suggesting the appearance of activated microglia. At 72 h
after MCAO, Iba1 immunoreactivity was further increased
around the lesion. In addition, Iba1-immunoreactive (Iba1-ir)
cells were visible within the infarct area (Fig. 7A). The distribution
of Iba1-ir cells was similar to that of TGF-b1-expressing cells at
each time point. Furthermore, a combination of Iba1 immuno-
histochemistry and TGF-b1 in situ hybridization indicated co-
localization of Iba1 and TGF-b1 within the ischemic core as well
as around the lesion (Fig. 7B). Approximately 95% of the TGF-b1
cells contained Iba1 immunoreactivity (Table 1). In contrast, the
distribution of TGF-b2- and -b3-expressing cells had different
distributions (Fig. 8A) and showed only minimal co-localization
with Iba1 (Table 1).
GFAP- and NeuN-ir cells were not present in the ischemic core,
but indicated the extent of the lesion by their presence in the intact
tissue. Approximately 25% of the TGF-b1-expressing cells around
the lesion were also labeled by GFAP (Fig. 7C) while only a very
small percentage of TGF-b2 (Fig. 8C) and-b3-expressing cells
contained GFAP immunoreactivity (Table 1). Over 80% of TGF-
b2 and –b3 mRNA-expressing cells co-localized with the NeuN-
positive cells suggesting that these subtypes are expressed in
neurons (Fig. 8B). In turn, TGF-b2 and –b3 were not present in
microglial cells as concluded from their absence in Iba1-ir cells
(Fig. 8A).
The Induction of Fos and ATF-3 in Neurons Expressing
TGF-bs after Transient MCAO
Fos-expressing neurons were present throughout the cerebral
cortex ipsilateral to the lesion 24 h after MCAO. However, the
distribution of Fos-ir cells showed some topographical organiza-
tion. The highest density of Fos-ir cells was observed in layer II
while layers I, IV, and VI contained only a few Fos-ir cells
(Fig. 9A). In contrast, intensely labeled ATF-3-ir cells were present
only around the lesion (Fig. 9B). We did not observe Fos or ATF-3
immunoreactivity in TGF-b1 mRNA expressing cells (Fig. 9C,D).
In contrast, almost all of the examined TGF-b2-expressing
neurons contained Fos immunoreactivity (Table 1), while other
Fos-ir cells did not express TGF-b2 (Fig. 9E). The area containing
ATF-3-ir cells only slightly overlapped with the area containing
TGF-b2-expressing cells. In these regions, ATF-3 immunoreac-
tivity did not substantially co-localize with TGF-b2 (Fig. 9F).
Discussion
Our findings indicate that TGF-bs are induced in the brain
following focal ischemic attack and that the mRNAs of the
different types of TGF-bs have individual topographical distribu-
tions in distinct cell types. We compare these patterns to the
distributions of previously published expressional data following
MCAO, and also provide additional information on the mecha-
nisms involved in the induction of these factors. Finally, our data
are discussed in terms of the potential functions of TGF-bs in brain
ischemia.
The Expression of the Different Subtypes of TGF-bs in the
Brain Following Focal Ischemia
The in situ hybridization probes were designed to recognize all
known forms of mRNA for each type of TGF-b. Therefore, the in
situ hybridization signals we obtained represent the sum of the
different alternatively spliced forms of each TGF-b that were
present in the tissue [45]. The results confirmed and expanded
previous findings related to the induction of TGF-b1 in response
to MCAO. A biphasic expression of TGF-b1 mRNA has been
reported following MCAO in rats [29]. In this study [29], in situ
hybridization of TGF-b1 was analyzed using film autoradiograms,
which does not allow the spatial resolution of our study.
Nevertheless, an early induction of TGF-b1 in the peri-infarct
cerebral cortex was followed by the induction of TGF-b1 within
the infarct. We confirmed these observations and also revealed an
early phase induction of TGF-b1 in the peri-infarct caudate
putamen. Furthermore, we demonstrated that the peri-infarct
localization of TGF-b1 is restricted to the penumbra. However, it
must be emphasized that our data demonstrate only the induction
of TGF-b mRNA. In the future, a validation of these results at the
protein level will be important to fully appreciate the potential role
of TGF-bs in ischemia.
The expression of TGF-b1 in microglia following MCAO has
previously been suggested using a combination of immunohisto-
chemistry for OX42 and in situ hybridization for TGF-b1 [33]. We
used Iba1, an established marker of both ramified and activated
microglia [46], to demonstrate the expression of TGF-b1 in
microglia. In contrast to the absence of TGF-b1 in astrocytes
reported by Lehrmann et al (1998), we observed TGF-b1 in some
GFAP-positive neurons confirming studies on the induction of
nuclei that do not express TGF-b2 can also be observed. F: TGF-b2 mRNA does not co-localize with ATF-3 immunoreactivity (brown cell nuclei).
Abbreviations: cc - corpus callosum, CP -caudate putamen, Cx - cerebral cortex, LV - lateral ventricle. Scale bars = 1 mm for B, 100 mm for C and D, and
50 mm for E and F.
doi:10.1371/journal.pone.0046731.g009
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TGF-b1 in astrocytes following transient ischemia [47]. In
addition, we used the neuronal marker NeuN to demonstrate
that TGF-b1 is not expressed in neurons, suggesting that the
induction of TGF-b1 is restricted to glial cells. The small
percentage of apparent co-localization could be the result of
single labeled cells situated above each other in different planes.
Furthermore, we first described the expression patterns of TGF-b2
and -b3 following focal ischemia and compared them to that of
TGF-b1. A marked difference was found; TGF-b2 and -b3 were
exclusively induced in specific layers of the cerebral cortex. In
those layers, however, the induction took place even in regions
remote from the lesion and outside of the penumbra in the
ipsilateral cortex. The level of TGF-b2 increased in cells that
already had basal TGF-b2 expression in layer V but also in newly
recruited cells in layer II and III of the cerebral cortex. The
induction patterns of TGF-b2 and -b3 were not biphasic; rather
they peaked at 24 h following MCAO and subsequently
decreased. Another major difference between the induction of
TGF-b1 and -b2 is that the latter was exclusively expressed in
neurons. Thus, the present study largely expanded our knowledge
regarding the induction of TGF-ßs following MCAO, as it is the
first to describe the expression of all 3 types of TGF-bs at different
time points following an ischemic attack.
Possible Mechanisms of Induction of TGF-ßs
As the induction of all 3 types of TGF-ßs became more
pronounced by permanent occlusion, as opposed to 1 h occlusion
followed by reperfusion, it is likely that ischemia itself rather than
reperfusion evokes the induction of TGF-ßs. The precise overlap
between the area of TGF-ß1 expression and the border of the
penumbra also suggests that ischemia itself leads to the induction
of TGF-ß1. Focal ischemic damage is known to activate microglia
in the infarct area, as well as in the adjacent surviving area [32] via
inflammatory cytokines released from ischemic neurons and
invading blood cells [48,49]. The expression of Iba1, which is
probably involved in the mobility and phagocytosis of microglia
[50], is enhanced after transient focal ischemia in microglia and in
macrophages that infiltrate the infarct area [51]. However,
microglial activation predominates over macrophage infiltration
following MCAO [52]. Therefore, it is likely that the increased
expression of TGF-ß1 is predominantly a consequence of
microglial activation, which is also supported by the appearance
of TGF-ß1 in the peri-infarct area. In fact, inflammatory cytokines
such as tumor necrosis factor-alpha and IL-1 have been shown to
induce TGF-ß1 expression in microglia and astrocytes [53,54].
The neuronal induction and the markedly different expression
patterns of TGF-b2 and -b3 from that of TGF-b1 suggest different
mechanisms of induction for these subtypes. The mechanisms of
induction were addressed using double labeling of TGF-b2 mRNA
with ATF-3 and Fos immediate early genes. Damage to axons was
shown to induce the activation of ATF-3 in the cell nuclei [55].
MCAO resulted in a very fast induction of ATF-3 within the
infarct area followed by the appearance of ATF-3 in the peri-
infarct area [56] that co-localized with neurons but not glial cells
[57]. However, the lack of co-localization of ATF-3 with TGF-bs
suggests that axonal damage is not as major factor in the induction
of TGF-bs. In contrast, TGF-b2-expressing cells had a distribution
similar to that of the c-fos activation pattern following MCAO
[58,59] suggesting a previous activation of these neurons [60,61].
Furthermore, the TGF-b2-expressing cells all contained Fos
immunoreactivity. As Fos expression can be caused by cortical
spreading depolarization following MCAO [62], it is likely that the
induction of TGF-b2 and -b3 occurs by cortical spreading
depolarization, possibly via c-fos activation. In cortical layers II
and V, some neurons in intact tissue expressed TGF-b2. It is
plausible that cortical spreading depolarization enhances the
expression levels of TGF-b2 in these neurons. However, the
recruitment of additional neurons is likely as TGF-b2 and TGF-
b3-expressing neurons also appear in layers III and II, respec-
tively.
Functional Implications of the Induction of TGF-bs
Following Focal Ischemia
TGF-bs have neuroprotective actions against hypoxic events as
demonstrated in different experimental model systems [16–19].
The different spatial and temporal patterns of TGF-b induction
following MCAO support their participation in distinct functions
after focal ischemic attack. TGF-b1 expression was elevated in the
ischemic penumbra, a major target of neuroprotective treatment
[63]. TGF-b1 may exert negative auto-feedback inhibitory action
on the function of microglia, which are required to not only
remove debris but also contribute to neuronal damage by releasing
oxygen species and inflammatory cytokines [64]. TGF-b1 can
deactivate microglia [65] and selectively promote their apoptosis
[66]. TGF-bs may also participate in other processes following
ischemia including neoangiogenesis [67,68] and glial scar forma-
tion [14]. Local injection of a TGF-b antagonist into cerebral
wounds reduced glial scarring [35] and abolished fibrinogen-
induced effects on glial scar formation [69], possibly by affecting
the proliferation, migration and activation of astrocytes [8,70] and
the extracellular matrix environment [71].
A direct neuroprotective function of the TGF-bs is also likely
based on their in vitro effects on neuronal survival [9,13,18]. These
actions may be mediated by different neurotrophic factors whose
actions are modulated by TGF-bs [10,72,73]. After ischemic
lesions, the restoration of neural functions may also require novel
neurite growth and synapse formation, processes that are also
influenced by the TGF-bs [74–76]. Many of these actions were
examined by techniques that did not differentiate between the
TGF-b subtypes. However, our results suggest separate functions
for the TGF-b subtypes. TGF-b2, co-expressed with Fos in the
cerebral cortex may be involved in the regulation of neuronal
apoptosis as cortical neurons are known to exhibit programmed
cell death following MCAO [77–80] and Fos expression is thought
to be a crucial part of the programmed cell death pathway and
whose inhibition was shown to be neuroprotective after MCAO
[81]. Given that TGF-b2 and -b3 inhibit hypoxia-induced
neuronal apoptosis [9,82], it is possible that induced cortical
TGF-b2 and -b3 exert neuroprotective functions by inhibiting
apoptosis in the ipsilateral cerebral cortex. In addition to neuronal
survival, TGF-bs might also be involved in neuronal repair, a
process increasingly investigated for post-stroke treatment [83].
Ischemia induced neural stem cell proliferation and differentiation
involves TGF-b pathways [84]. In turn, TGF-bs increased the
expression of neuronal markers in cortical primary cell cultures
[27], as well as during adult neurogenesis [26].
Conclusions
Endogenous TGF-b1, -b2 and -b3 are expressed in brain tissue
following a focal ischemic lesion caused by MCAO. However,
significant differences exist between the spatial and temporal
patterns of expression of TGF-b subtypes. Furthermore, the TGF-
b subtypes are expressed in separate cell types, and co-localize
with different immediate early genes, suggesting that their
inductions following an ischemic attack requires distinct mecha-
nisms. These results imply that the different subtypes of TGF-bs
participate in different aspects of neural tissue protection.
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